Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freeport-McMoRan Inc (FCX) vs Invesco Ltd. (IVZ) Price & Performance

Freeport-McMoRan IncTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

Freeport-McMoRan Inc vs Invesco Ltd. — how do they compare? Freeport-McMoRan Inc trades at $73.22 (market cap $102.16B), while Invesco Ltd. trades at $30.09 (market cap $13.28B). The key difference: Freeport-McMoRan Inc is far larger — about 7.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.86%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Invesco Ltd. for 77 Days on average.

FCXIVZ
Market Cap
$102.16B$13.28B
Volume
9,047,9713,698,033
Sector
Basic MaterialsFinancials
52-Week High
$79.91$33.31
52-Week Low
$38.65$22.44
Typical Hold Time
69 Days77 Days
Enterprise Value
$108.44B$23.45B
Dividend Yield
0.84%2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freeport-McMoRan Inc

FCX trades at $71.87, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $73.27. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue for 2025 was $25.92 billion, with net income of $2.20 billion and a net margin of 11.38%. Recent news highlights strong copper demand driven by AI and data center growth, positioning FCX to benefit from favorable market trends.

The outlook for FCX is positive, supported by robust copper demand and expansion projects, but risks include rising production costs and potential regulatory investigations. Analyst sentiment is predominantly bullish, with 61% recommending buy. The stock offers growth potential from commodity tailwinds, though investors should monitor cost pressures and execution of growth initiatives.

Invesco Ltd.

Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.

The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FCX
46% Buy54% Sell
Avg holding period · 69 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About Freeport-McMoRan Inc

Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia

Read more on FCX →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →